Navigation Links
Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
Date:11/5/2012

BOULDER, Colo., Nov. 5, 2012 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2012 Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. Array will also hold a conference call today, Monday, November 5, 2012 at 4:30 p.m. ET, to review the abstracts.  The call-in details are provided below. 

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Ron Squarer, Chief Executive Officer of Array, noted, "We are excited to present clinical results for ARRY-520 and ARRY-614 at the upcoming ASH annual meeting.  Notably, our oral presentation will show that in patients with triple-refractory multiple myeloma and a median number of 10 prior treatment regimens, ARRY-520 plus low-dose dexamethasone has a 22% overall response rate (≥PR), with manageable safety.  This response rate is comparable to those reported for pomalidomide or carfilzomib even though their studies included patients with only half the number of prior median treatment regimens.  In a related abstract assessing the same group of ARRY-520-treated patients, we observed that prospective screening for the acute phase protein alpha-1-acidic glycoprotein, or AAG, may enable us to better select patients who will respond to treatment with ARRY-520.  For patients with a non-elevated AAG level, the overall response rate (≥PR) increased to 33%. We believe these observed overall response rates in a heavily pre-treated patient population with limited treatment options defines a potential regulatory path to approval for ARRY-520."  

ARRY‑520 is currently advancing in three clinical trials. Positive results in any one o
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
10. CeNeRx BioPharma Completes $4.85 Million Financing
11. PDL BioPharma Completes Regular Quarterly Dividend Payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... WI (PRWEB) , ... September 01, 2015 , ... In ... Venice expertly transports the reader to a not-so-distant future faced with an Ebola pandemic ... beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, and who ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new Clinical ... joint problems can be caused by injuries and abnormalities of the cervical spine. ... or of the spinal cord itself. This can manifest itself as any or ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, ... and pain management space join prominent academics and key investors for Neuro Advance ... Medical School in Boston. , Neuro Advance Boston focuses on the latest ...
(Date:9/1/2015)... N.C. , Sept. 1, 2015   ... to facilitating the relationship between doctors and patients, ... Durham, N.C. -based venture capital ... strength and business association with Bull City Venture ... Malik , Medfusion Founder and Executive Chairman. "Both ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... PALO ALTO, Calif., Sept. 26 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... New York, NY on October 8,2007 at 8:00 ... the presentation may be accessed by visiting the,Investors ...
... announced,today that Mr. Jeffrey H. Buchalter has been ... With more than 20 years of experience in,product ... Mr. Buchalter is well poised to work with ... toward,commercializing its pipeline. "We are honored that ...
... Deal Includes up to $100MM in License Fees ... 26 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), ... with Japan Tobacco Inc. (JT) (TSE: 2914) and ... business subsidiary,under which JT and Torii will hold ...
Cached Biology Technology:Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 2Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 3Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 4
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... "intriguing" discovery that a natural plant hormone, applied to ... The study is scheduled for the Sept. 23 issue ... , a bi-weekly publication. Jing Quan Yu and ... production for the world,s growing population. Farmers worldwide use ...
... of Standards and Technology (NIST) has demonstrated a ... elusive hazards such as concealed explosives and toxins, ... soil by wind and rain. The prototype method ... traces of these materials, which are polarlike water ...
... to be able to find explosive materials and persons ... such searches, the National Institute of Standards and Technology ... has developed a new certified reference material, Standard Reference ... and laboratory assay methods, the SRM will be helpful ...
Cached Biology News:Prototype NIST method detects and measures elusive hazards 2New NIST trace explosives standard slated for homeland security duty 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Biology Products: